{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T15:30:09Z","timestamp":1792164609947,"version":"4.4.0"},"reference-count":16,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7_suppl_2","content-domain":{"domain":["neurology.org"],"crossmark-restriction":true},"short-container-title":["Neurology"],"published-print":{"date-parts":[[2006,10,10]]},"DOI":"10.1212\/wnl.67.7_suppl_2.s18","type":"journal-article","created":{"date-parts":[[2012,5,13]],"date-time":"2012-05-13T14:45:05Z","timestamp":1336920305000},"update-policy":"https:\/\/doi.org\/10.1212\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":165,"title":["Safinamide"],"prefix":"10.1212","volume":"67","author":[{"given":"C.","family":"Caccia","sequence":"first","affiliation":[{"name":"From Newron Pharmaceuticals Spa, Bresso (MI), Italy (C.C., M.C., S.M., L.F., L.C., P.S., R.G.F.), and Mondo Biotech, Gentilino, Switzerland (R.M.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Maj","sequence":"additional","affiliation":[{"name":"From Newron Pharmaceuticals Spa, Bresso (MI), Italy (C.C., M.C., S.M., L.F., L.C., P.S., R.G.F.), and Mondo Biotech, Gentilino, Switzerland (R.M.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Calabresi","sequence":"additional","affiliation":[{"name":"From Newron Pharmaceuticals Spa, Bresso (MI), Italy (C.C., M.C., S.M., L.F., L.C., P.S., R.G.F.), and Mondo Biotech, Gentilino, Switzerland (R.M.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Maestroni","sequence":"additional","affiliation":[{"name":"From Newron Pharmaceuticals Spa, Bresso (MI), Italy (C.C., M.C., S.M., L.F., L.C., P.S., R.G.F.), and Mondo Biotech, Gentilino, Switzerland (R.M.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Faravelli","sequence":"additional","affiliation":[{"name":"From Newron Pharmaceuticals Spa, Bresso (MI), Italy (C.C., M.C., S.M., L.F., L.C., P.S., R.G.F.), and Mondo Biotech, Gentilino, Switzerland (R.M.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Curatolo","sequence":"additional","affiliation":[{"name":"From Newron Pharmaceuticals Spa, Bresso (MI), Italy (C.C., M.C., S.M., L.F., L.C., P.S., R.G.F.), and Mondo Biotech, Gentilino, Switzerland (R.M.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Salvati","sequence":"additional","affiliation":[{"name":"From Newron Pharmaceuticals Spa, Bresso (MI), Italy (C.C., M.C., S.M., L.F., L.C., P.S., R.G.F.), and Mondo Biotech, Gentilino, Switzerland (R.M.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. G.","family":"Fariello","sequence":"additional","affiliation":[{"name":"From Newron Pharmaceuticals Spa, Bresso (MI), Italy (C.C., M.C., S.M., L.F., L.C., P.S., R.G.F.), and Mondo Biotech, Gentilino, Switzerland (R.M.)."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_1_2_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.51.1.2"},{"key":"e_1_3_1_3_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.58.2.179"},{"key":"e_1_3_1_4_2","doi-asserted-by":"publisher","DOI":"10.1051\/jbio\/2002196010095"},{"key":"e_1_3_1_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.10487"},{"key":"e_1_3_1_6_2","first-page":"S17","volume":"50","year":"1998","unstructured":"Chase TN. Levodopa therapy: consequences of the nonphysiologic replacement of dopamine. Neurology 1998;50:S17\u2013S25.","journal-title":"Neurology"},{"key":"e_1_3_1_7_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000058760.13152.1A"},{"key":"e_1_3_1_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.10488"},{"key":"e_1_3_1_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.10483"},{"key":"e_1_3_1_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.10481"},{"key":"e_1_3_1_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.10403"},{"key":"e_1_3_1_12_2","first-page":"S89","volume":"44","year":"1998","unstructured":"Schapira AH, Gu M, Taanman JW, et al. Mitochondria in the etiology and pathogenesis of Parkinson's disease. Ann Neurol 1998;44(3 suppl 1):S89\u2013S98.","journal-title":"Ann Neurol"},{"key":"e_1_3_1_13_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1471-4159.1997.68010033.x"},{"key":"e_1_3_1_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-4159.1986.tb01747.x"},{"key":"e_1_3_1_15_2","first-page":"S23","volume":"63","year":"2004","unstructured":"LeWitt PA. Clinical trials of neuroprotection for Parkinson's disease. Neurology 2004;63(7 suppl 2):S23\u2013S31.","journal-title":"Neurology"},{"key":"e_1_3_1_16_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198911163212004"},{"key":"e_1_3_1_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(94)90796-X"}],"container-title":["Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.neurology.org\/doi\/full\/10.1212\/WNL.67.7_suppl_2.S18","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,28]],"date-time":"2024-03-28T16:49:00Z","timestamp":1711644540000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.neurology.org\/doi\/10.1212\/WNL.67.7_suppl_2.S18"}},"subtitle":["From molecular targets to a new anti-Parkinson drug"],"short-title":[],"issued":{"date-parts":[[2006,10,10]]},"references-count":16,"journal-issue":{"issue":"7_suppl_2","published-print":{"date-parts":[[2006,10,10]]}},"alternative-id":["10.1212\/WNL.67.7_suppl_2.S18"],"URL":"https:\/\/doi.org\/10.1212\/wnl.67.7_suppl_2.s18","relation":{},"ISSN":["0028-3878","1526-632X"],"issn-type":[{"value":"0028-3878","type":"print"},{"value":"1526-632X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,10,10]]}}}